-
Baird Sees 'Improved Odds' Tandem Diabetes Care Will Survive
Friday, March 23, 2018 - 2:41pm | 418Tandem Diabetes Care Inc (NASDAQ: TNDM), a medical technology company focused on the treatment of diabetes and insulin infusion therapy, has seen transformed from a "solid competitive" company in mid-2016 to one where it might not survive, according to Baird. But the company may boast the...
-
First Data A New 'Fresh Pick' At Baird As Various Financial Metrics Continue To Improve
Monday, March 19, 2018 - 3:37pm | 327First Data Corp (NYSE: FDC)'s stock is up just 3 percent over the past year, but multiple improving financial metrics supports the bullish case for owning the stock. The Analyst Baird Equity Research's David Koning maintains an Outperform rating on First Data with an unchanged $22...
-
Baird Turns Incrementally Bullish On Micron, Cites Stronger Memory Outlook
Friday, March 16, 2018 - 11:45am | 421Shares of Micron Technology, Inc. (NASDAQ: MU) have gained more than 45 percent since the beginning of the year, but the stock still has room to run, according to Baird. The Analyst Baird Equity Research's Tristan Gerra maintains an Outperform rating on Micron's stock with a price target...
-
Baird: Prospects For Proteostasis Therapeutics' PTI-428 Are Not Priced Into The Stock
Friday, March 16, 2018 - 10:59am | 442Even after Wednesday’s 31-percent run, a Baird analyst forecast 300-percent upside to Proteostasis Therapeutics Inc (NASDAQ: PTI). By the analyst's assessment, the market hasn’t fully appreciated the biotech’s PTI-428 candidate. The Rating Baird Equity Research analyst Brian...
-
Sportsman's Warehouse CEO Resignation Prompts Downgrade At Baird
Thursday, March 15, 2018 - 12:47pm | 394Sportsman's Warehouse Holdings Inc (NASDAQ: SPWH), an outdoor sporting goods retailer, said Wednesday CEO John Schaefer resigned from the company and will be replaced by Jon Barker, the company's president and chief operating officer. While the transition plan has been known for years, the...
-
Parker-Hannifin's 5-Year Outlook Impresses Analysts
Thursday, March 8, 2018 - 4:52pm | 594Two Wall Street analysts took a favorable view this week of Parker-Hannifin Corp (NYSE: PH)'s updated five-year outlook. The Analysts KeyBanc Capital Markets' Jeffrey Hammond maintains an Overweight rating on Parker-Hannifin stock with an unchanged $225 price target. Baird...
-
Costco 'Has The Tools To Compete And Win': Analysts React To Retailer's Q2 Report
Thursday, March 8, 2018 - 3:56pm | 914Shares of Costco Wholesale Corporation (NASDAQ: COST) were trading lower by nearly 2 percent early Thursday afternoon after the company reported an earnings beat in its fiscal second quarter with revenue that fell slightly short of expectations. Rating, Price Target Changes Wells...
-
Amid Fragmented Pizza Market, Domino's Still Has Room To Grow
Tuesday, March 6, 2018 - 1:52pm | 427Domino's Pizza, Inc. (NYSE: DPZ) boasts a longer-term growth story in a sizable and fragmented global pizza market coupled with minimum downside in the stock, according to Wall Street's newest bull analyst. The Analyst Baird Equity Research's David Tarantino initiated coverage of...
-
Here's What Wall Street Thinks Of Splunk's Q4 Earnings
Friday, March 2, 2018 - 2:34pm | 631Splunk Inc (NASDAQ: SPLK) reported a top-and-bottom-line beat in its fourth quarter results, which had multiple Wall Street analysts upbeat over the company's outlook. Price Target And Rating Changes Credit Suisse's Brad Zelnick: Outperform rating, price target raised from $88 to $110...
-
How A Walgreens-AmerisourceBergen Combo Stacks Up Against CVS-Aetna
Tuesday, February 13, 2018 - 3:37pm | 1045Some see Walgreens Boots Alliance Inc (NASDAQ: WBA)’s reported pursuit of AmerisourceBergen Corp. (NYSE: ABC) as a smart defensive play. The purchase would cut costs in the drug supply chain, increase appeal with pharmacy benefit managers and insurers and strengthen the drugstore operator...
-
Analyst: Regeneron Is Undervalued By The Street
Friday, February 9, 2018 - 11:46am | 466Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has been in steady decline since July, and one analyst, though conceding the selloff from $500 was justified, said the Street’s taken it too far. The Rating Baird Equity Research analyst Brian Skorney upgraded Regeneron from Neutral to Outperform...
-
Baird Says Canada Goose Sell-Off Is Unwarranted, Upgrades To Outperform
Friday, February 9, 2018 - 11:23am | 426Canada Goose Holdings Inc. Subordinate Voting Shares (NYSE: GOOS) reported its fiscal third-quarter results Thursday, with a top-and-bottom-line beat — yet shares ended the trading session lower by more than 15 percent. The Analyst Baird Equity Research's Jonathan Komp...
-
Wall Street Analysts Reflect On Tesla's Q4 Earnings
Thursday, February 8, 2018 - 2:58pm | 953Tesla Inc (NASDAQ: TSLA) posted marginal top- and bottom-line beats in its Wednesday earnings report, and traders retreated Thursday with a 5-percent pullback. Analysts reflected on the quarter with similar ambivalence. The Cash Situation Nomura analyst Romit Shah considered the report decidedly...
-
Tesla's New Compensation Pushes Elon Musk To Focus On Profitability, Baird Says
Wednesday, January 24, 2018 - 1:21pm | 459Tesla Inc (NASDAQ: TSLA) skeptics have long anticipated the defection of CEO Elon Musk to the peripheral ventures of SpaceX and The Boring Company. Musk’s departure, they’ve said, would derail Tesla's leader-centric story. But the auto and electric power company challenged the bear...
-
Baird Gets Bullish On Digital Realty After Recent Pullback
Tuesday, January 16, 2018 - 11:58am | 398Shares of Digital Realty Trust, Inc. (NYSE: DLR) have lost more than 5 percent since the start of 2018, which prompted one analyst to encourage investors to buy the stock on the dip. The Analyst Baird Equity Research's David Rodgers upgraded Digital Realty Trust's stock from Neutral...